SEARCH

SEARCH BY CITATION

References

  • ALVES-RODRIGUES, A., LEURS, R., WU, T.S., PRELL, G.D., FOGED, C. & TIMMERMAN, H. (1996). 3H-thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex. Br. J. Pharmacol., 118, 20452052.
  • APELT, J., LIGNEAU, X., PERTZ, H.H., ARRANG, J.-M., GANELLIN, C., SCHWARTZ, J.-C., SCHUNACK, W. & STARK, H. (2002). Development of a new class of nonimidazole histamine H3 receptor ligands with combined inhibitory histamine N-methyltransferase activity. Bioorg. Med. Chem. Lett., 13, 17671770.
  • APODACA, R., DVORAK, C.A., XIAO, W., BARBIER, A.J., BOGGS, J.D., WILSON, S.J., LOVENBERG, T.W. & CARRUTHERS, N.I. (2003). A new class of diamine-based human histamine H3 receptor ligands: 4-(aminoalkoxy)-benzylamines. J. Med. Chem., 46, 39383944.
  • ARRANG, J.M., GARBARG, M. & SCHWARTZ, J.-C. (1983). Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (Lond.), 302, 832837.
  • ARRANG, J.M., GARBARG, M. & SCHWARTZ, J.-C. (1987). Autoinhibition of histamine synthesis mediated by presynaptic H3 receptors. Neuroscience, 23, 149157.
  • ATTOUB, S., MOIZO, L., SOBHANI, I., LAIGNEAU, J.-P., LEWIN, M.J.M. & BADO, A. (2001). The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci., 69, 469478.
  • BERRIDGE, C.W. & FOOTE, S.L (1996). Enhancement of behavioral and electroencephalographic indices of waking following stimulation of noradrenergic beta-receptors within the medial septal region of the basal forebrain. J. Neurosci., 16, 69997009.
  • BONAVENTURE, P., NEPOMUCENO, D., KWOK, A., CHAI, W., LANGLOIS, X., HEN, R., STARK, K., CARRUTHERS, N.I. & LOVENBERG, T.W. (2002). Reconsideration of 5-hydroxytryptamine (5-HT)7 receptor distribution using [3H]5-carboxamidotryptamine and [3H]8-hydroxy-2-(di-n-propylamino)tetraline: analysis in brain of 5-HT1A knockout and 5-HT1A/1B double-knockout mice. J. Pharmacol. Exp. Ther., 302, 240248.
  • BROWN, R.E., STEVENS, D.R. & HAAS, H.L. (2001). The physiology of brain histamine. Progr. Neurobiol., 63, 637672.
  • CHENG, Y.-C. & PRUSOFF, W.H. (1973). Relation between the inhibition constant and Ki and the concentration of inhibitors which causes fifty per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 22, 30993108.
  • CHILDERS, S.R. & SNYDER, S.H. (1980). Differential regulation by guanine nucleotides or opiate agonist and antagonist interactions. J. Neurochem., 34, 583593.
  • EDGAR, D.M. & SEIDEL, W.F. (1997). Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J. Pharmacol. Exp. Ther., 283, 757769.
  • ESBENSHADE, T., KRUEGER, K., DENNY, L.I., MILLER, T., KANG, C.H., WITTE, D., YAO, B., BLACK, L., BENNANI, Y., FOX, G.B., PAN, J.B., DECKER, M.W. & HANCOCK, A. (2001). Complex pharmacological effects of GT-2331. Soc. Neurosci., abstract 378.1.
  • FAGHIH, R., DWIGHT, W., GENTLES, R., PHELAN, K., ESBENSHADE, T.A., IRELAND, L., MILLER, T.R., KANG, C.-H., FOX, G.B., GOPALAKRISHNAN, S.M., HANCOCK, A.A. & BENNANI, Y.L. (2002). Structure–activity relationships of non-imidazole histamine H3 receptor ligands. Part I. Bioorg. Med. Chem. Lett., 12, 20312034.
  • FOX, G.B., PAN, J.B., ESBENSHADE, T.A., BENNANI, Y.L., BLACK, L.A., FAGHIH, R., HANCOCK, A.A. & DECKER, M.W. (2002). Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res., 131, 151161.
  • HANCOCK, A.A. (2003). H3 receptor antagonists/inverse agonists as anti-obesity agents. Curr. Opin. Invest. Drugs., 4, 11901197.
  • HANCOCK, A.A., BENNANI, Y.L., BUSH, E.N., ESBENSHADE, T.A., FAGHIH, R., FOX, G.B., JACOBSON, P., KNOUREK-SEGEL, V., KRUEGER, K.M., NUSS, M.E., PAN, J.B., SHAPIRO, R., WITTE, D.G. & YAO, B.M. (2004). Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur. J. Pharmacol., 487, 183197.
  • HANCOCK, A.A., BUSH, E.N., SHAPIRO, R., NUSS, M., SEGEL, V., WILCOX, D.M., DROZ, B., DICKINSON, R.W., JACOBSON, P.B., BENNANI, Y.L., ESBENSHADE, T.A. & FAGHIH, R. (2003). Antiobesity effects of novel, non-imidazole histamine H3 receptor antagonists exemplified by A-331440. Abstract 3, Abstract Book of the American Chemical Society. 225th National Meeting, New Orleans, LA, March 25–27, 2003.
  • HOFSTRA, C.L., DESAI, P.J., THURMOND, R.L. & FUNG-LEUNG, W.P. (2003). Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther., 305, 12121221.
  • ITOH, E., FUJIMIYA, M. & INUI, A. (1999). Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol. Psych., 45, 475481.
  • LANGLOIS, X, TE RIELE, P., WINTMOLDERS, C., LEYSEN, J.E. & JURZAK, M. (2001). Use of the β-Imager for rapid ex-vivo autoradiography exemplified with CNS penetrating neurokinin 3 antagonists. J. Pharmacol. Exp. Ther., 299, 712717.
  • LIGNEAU, X., LIN, J.-S., VANNI-MERCIER, G., JOUVET, M., MUIR, J.L., GANELLIN, C.R., STARK, H., ELZ, S., SCHUNACK, W. & SCHWARTZ, J.-C. (1998). Neurochemical and behavioral effects of ciproxifan, a potent histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther., 287, 658666.
  • LIN, J.S., HOU, Y., SAKAI, K. & JOUVET, M. (1996). Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J. Neurosci., 16, 15231537.
  • LIN, J.S., SAKAI, K. & JOUVET, M. (1994). Hypothalamo-preoptic histaminergic projections in sleep–wake control in the cat. Eur. J. Neurosci., 6, 618625.
  • LIN, J.S., SAKAI, K., VANNI-MERCIER, G., ARRANG, J.M., GARBARG, M., SCHWARTZ, J.C. & JOUVET, M. (1990). Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res., 523, 325330.
  • LINNEY, I.D., BUCK, I.M., HARPER, E.A., KALINDJIAN, S.B., PETHER, M.J., SHANKLEY, N.P., WATT, G.F. & WRIGHT, P.T. (2000). Design, synthesis and structure–activity relationships of novel non-imidazole histamine H3 receptor antagonists. J. Med. Chem., 43, 23622370.
  • LOVENBERG, T.W., PYATI, J., CHANG, H., WILSON, S.J. & ERLANDER, M.G. (2000). Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther., 293, 771778.
  • MCLEOD, R.L., ASLANIAN, R., DEL PRADO, M., DUFFY, R., EGAN, R.W., KREUTNER, W., MCQUADE, R. & HEY, J.A. (1998). Sch 50971, an orally active histamine H3 receptor agonist inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. J. Pharmacol. Exp. Ther., 287, 4350.
  • MARTIN, N.A., RUCKLE, M.B., VANHOOF, S.L. & PRATHER, P.L. (2002). Agonist, antagonist and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective δ-opioid receptor ligand. J. Pharmacol. Exp. Ther., 301, 661671.
  • MOCHIZUKI, T., YAMATODANI, A., OKAKURA, K., HORII, A., INAGAKI, N. & WADA, H. (1992). Circadian rhythm of histamine release from the hypothalamus of freely moving rats. Physiol. Behav., 51, 391394.
  • MONTI, J.M., D'ANGELO, L., JANTOS, H. & PRAZOS, S. (1988). Effects of α-fluoromethylhistidine on sleep and wakefulness in the rat. J. Neural Transm., 72, 141145.
  • MONTI, J.M., JANTOS, H., BOUSSARD, M., ALTIER, H., ORELLANA, C. & OLIVERA, S. (1991). Effects of selective activation or blockade of the histamine H3 receptor on sleep and wakefulness. Eur. J. Pharmacol., 205, 283287.
  • MONTI, J.M., JANTOS, H., PONZONI, A. & MONTI, D. (1996). Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology, 15, 3135.
  • MONTI, J.M., PELLEJERO, T. & JANTOS, H. (1986). Effects of H1 and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J. Neural Transm., 66, 111.
  • MORISSET, S., ROULEAU, A., LIGNEAU, X., GBAHOU, F., TARDIVEL-LACOMBE, J., STARK, H., SCHUNACK, W., GANELLIN, C.R., SCHWARTZ, J.-C. & ARRANG, J.-M. (2000). High constitutive activity of native H3 receptors regulates histamine neurons in the brain. Nature, 408, 860864.
  • PARMENTIER, R., OHTSU, H., DJEBBARA-HANNAS, Z., VALATX, J.L., WATANABE, T. & LIN, J.S. (2002). Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep–wake control. J. Neurosci., 22, 76957711.
  • PILLOT, C., HERON, A., COCHOIS, V., TARDIVEL-LACOMBE, J., LIGNEAU, X., SCHWARTZ, J.-C. & ARRANG, J.-M. (2002). A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neuroscience, 114, 173193.
  • SHAH, C., MCATEE, L., BREITENBUCHER, J.G., RUDOLPH, D., LI, X., LOVENBERG, T.W., MAZUR, C., WILSON, S.J. & CARRUTHERS, N.I. (2002). Novel human histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett., 13, 17671770.
  • SILVER, R.B., POONWASI, K.S., SEYEDI, N., WILSON, S.J., LOVENBERG, T.W. & LEVI, R. (2002). Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norephinephrine exocytosis from cardiac sympathetic nerve endings. Proc. Natl. Acad. Sci. U.S.A., 99, 501506.
  • STARK, H., SCHLICKER, E. & SCHUNACK, W. (1996). Developments of histamine H3-receptor antagonists. Drugs Future, 21, 507520.
  • TAKAHASHI, K., SUWA, H., ISHIKAWA, T. & TOKANI, K. (2002). Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J. Clin. Invest., 110, 17911799.
  • TEDFORD, C.E., EDGAR, C.M., SEIDEL, W.F., MIGNOT, E., NISHINO, S., PAWLOWSKI, G.P. & YATES, S.L. (2000). Effects of a novel, selective and potent histamine H3 receptor antagonist, GT-2331, on rat sleep–wakefulness and canine cataplexy. Soc. Neurosci. Abs., 26, 460.3.
  • TOYOTA, H., DUGOVIC, C., KOEHL, M., LAPOSKY, A.D., WEBER, C., NGO, K., WU, Y., LEE, D.H., YANAI, K., SAKURAI, E., WATANABE, T., LIU, C., CHEN, J., BARBIER, A.J., TUREK, F.W., FUNG-LEUNG, W.-P. & LOVENBERG, T.W. (2002). Behavioral characterization of mice lacking histamine H3 receptors. Mol. Pharmacol., 62, 389397.
  • VANNI-MERCIER, G., GIGOUT, S., DEBILLY, G. & LIN, J.S. (2003). Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. Behav. Brain Res., 144, 227241.
  • WALCZYNSKI, K., GURYN, R., ZUIDERVELD, O.P. & TIMMERMAN, H. (1999). Non-imidazole H3 ligands. Part I. Synthesis of 2-(1-piperazinyl)- and 2-(hexahydro-1H-1,4,diazepin-1-yl) benzthiazole derivatives as H3 antagonists with H1 blocking activities. Farmako, 54, 684694.
  • WIELAND, K., BONGERS, G., YAMAMOTO, Y., HASHIMOTO, T., YAMATODANI, A., MENGE, W.M.B.P., TIMMERMAN, H., LOVENBERG, T.W. & LEURS, R. (2001). Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. J. Pharmacol. Exp. Ther., 299, 908914.
  • YATES, S.L., POWLOWSKI, G.P., BABU, J.S., RAJAGOPALAN, R., WAWRO, W.J. & TEDFORD, C.E. (2003). Inverse agonists of the histamine H3 receptor as appetite suppressants. Abstract 2, Abstract Book of the American Chemical Society. 225th National Meeting, New Orleans, LA, March 25–27, 2003.
  • YOSHIMATSU, H., ITATEYAMA, E., KONDOU, S., TAJIMA, D., HIMENO, K., HIDAKA, S., KUROKAWA, M. & SAKATA, T. (1999). Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes, 48, 22862291